Rnai Therapeutics Market Scope And Analysis

  • Report Code : TIPRE00007157
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

RNAi Therapeutics Market Scope and Analysis Report by 2031

Buy Now

RNAi Therapeutics Market Report RNAi Therapeutics Market Size and Share RNAi Therapeutics Market Scope and Analysis

RNAi Therapeutics Market Report Scope

Report Attribute Details
Market size in 2021 US$ 1.5 Billion
Market Size by 2031 US$ 3.2 Billion
Global CAGR (2023 - 2031) 16.5%
Historical Data 2021-2022
Forecast period 2023-2031
Segments Covered By Molecule Type
  • Small Interfering RNAs
  • MicroRNA
By Application
  • Genetic Disorders
  • Oncology
  • Neurodegenerative Disorders
  • Cardiovascular
  • Respiratory Disorders
  • Infectious Diseases
  • Renal Diseases
By Route of Administration
  • Intradermal Injections
  • Pulmonary Delivery
  • Intravenous Injections
  • Intraperitoneal Injections
By End User
  • Diagnostic Laboratories
  • Research & Academic Laboratories
  • Hospitals
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Alnylam Pharmaceuticals Inc
  • Sanofi
  • Olix Pharmaceuticals Inc
  • GlaxoSmithKline Plc
  • Benitec Biopharma
  • Arbutus Biopharma Corporation
  • Silence Therapeutics
  • Rexahn Pharmaceuticals Inc
  • Arrowhead Pharmaceuticals Inc
  • Quark

    • RNAi TherapeuticsMarket News and Recent Developments

    The RNAi TherapeuticsMarket is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in them market for RNAi Therapeutics and strategies:

    • In April 2024, Novartis, announced launching of "Leqvio" to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting thereby reducing the low-density lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease (ASCVD).

    RNAi TherapeuticsMarket Report Coverage and Deliverables

    The “RNAi TherapeuticsMarket Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Market dynamics such as drivers, restraints, and key opportunities
    • Key future trends
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
    • Detailed company profiles